Related Experiment Videos
Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies
1Department of Hematology/Oncology, University of Southern California School of Medicine, Los Angeles.
Molecular Biotherapy
|June 1, 1990
Abstract:
A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.